Compare Eos Energy Enterprises Inc (EOSE) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eos Energy Enterprises Inc vs Merck & Co., Inc. — how do they compare? Eos Energy Enterprises Inc trades at $2.8 (market cap $1.01B), while Merck & Co., Inc. trades at $142.58 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 347.8× Eos Energy Enterprises Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eos Energy Enterprises Inc for 16 Days and Merck & Co., Inc. for 98 Days on average.
| EOSE | MRK | |
|---|---|---|
Market Cap | $1.01B | $351.28B |
Volume | 39,626,541 | 7,969,665 |
Sector | Industrials | Health |
52-Week High | $19.19 | $156.43 |
52-Week Low | $2.77 | $82.49 |
Typical Hold Time | 16 Days | 98 Days |
Enterprise Value | $1.34B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $3.10, down 4.91% today, amid a bearish technical signal. The company is in a high-growth phase, with revenue surging from $114 million in 2025 to $214 million in 2026, but it remains deeply unprofitable, with a net income margin of -246.76% in 2026. Recent positive developments include a major partnership with Google for a $350 million West Virginia project and an $87 million Department of Energy loan advance to expand manufacturing capacity.
The outlook is a high-risk, high-reward proposition. Significant revenue growth and strategic partnerships offer substantial upside potential, with a consensus price target of $7.10. However, persistent negative cash flow from operations, high debt-to-asset ratio of 91.87%, and intense competition in the energy storage sector pose severe risks to shareholder value.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
